College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):654-61. doi: 10.1097/MNH.0b013e32834b7ffa.
Urinary proteomics has emerged as an approach that could deliver relevant clinical information. In this review, we aim at highlighting the recent developments, especially with respect to clinical implementation. We review several of the recent publications reporting on larger cohorts, focusing on those that aim at qualification and/or validation of urinary proteomics biomarkers.
Several components of the urinary proteome, especially its low molecular weight fraction (sometimes referred to as the 'peptidome'), have been significantly associated with chronic kidney disease (CKD). Independent studies, encompassing sometimes close to 1000 independent samples, indicate that specific peptides from extracellular matrix (ECM) proteins encompass a major component of the urinary proteome. Highly significant changes in the abundance of some of these peptides are associated with CKD indicating that alterations in ECM, reflected via the urinary proteome, may represent an early stage in CKD pathology. These peptides may serve as specific early biomarkers, and interference with pathological ECM accumulation may be a valuable new therapeutic approach in CKD.
Urinary proteomic biomarkers have emerged as clinically relevant variables. First studies involving several hundred individuals indicate a potential added benefit of urinary proteomic biomarkers. First large clinical trials are being initiated to employ urinary proteomics in clinical decision making.
尿蛋白质组学已成为一种可能提供相关临床信息的方法。在这篇综述中，我们旨在强调最近的发展，特别是在临床应用方面。我们回顾了一些最近的出版物，这些出版物报告了更大的队列，重点关注那些旨在对尿蛋白质组生物标志物进行定性和/或验证的研究。
尿蛋白质组的几个组成部分，特别是其低分子量部分（有时称为“肽组”），与慢性肾脏病（CKD）显著相关。独立的研究，包括有时接近 1000 个独立样本，表明细胞外基质（ECM）蛋白的特定肽是尿蛋白质组的主要组成部分。这些肽中一些的丰度发生了高度显著的变化，与 CKD 相关，表明通过尿蛋白质组反映的 ECM 改变可能代表 CKD 病理的早期阶段。这些肽可能作为特异性早期生物标志物，干扰病理性 ECM 积聚可能是 CKD 的一种有价值的新治疗方法。
尿蛋白质组生物标志物已成为具有临床相关性的变量。涉及数百人的初步研究表明，尿蛋白质组生物标志物可能具有额外的益处。首次大型临床试验正在启动，将尿蛋白质组学用于临床决策。
